Report cover image

Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 209 Pages
SKU # APRC20279890

Description

Summary

According to APO Research, the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) sales, projected growth trends, production technology, application and end-user industry.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Amgen
Mylan
Kashiv BioSciences
Pfizer
Fresenius Kabi
Coherus BioSciences
Sandoz
Italfarmaco SpA
Evive Biotech
Chugai Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Lenograstim
Pegfilgrastim
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Hospital and Clinic
Pharmacy
Other
Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) significant trends, drivers, influence factors in global and regions.
6. To analyze Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) industry.
Chapter 3: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

209 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
1.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume (2020-2031)
1.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
2.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Company
3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Revenue Ranking in 2024
3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2020-2025)
3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Company (2020-2025)
3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Company (2020-2025)
3.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Ranking (2023-2025)
3.6 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Manufacturing Base and Headquarters
3.7 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Product Type and Application
3.8 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
4.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Type Introduction
4.1.1 Lenograstim
4.1.2 Pegfilgrastim
4.1.3 Other
4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type
4.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2020-2031)
4.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2020-2031)
4.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type
4.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2020-2031)
4.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2020-2031)
5 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
5.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Application Introduction
5.1.1 Hospital and Clinic
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application
5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2020-2031)
5.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2020-2031)
5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application
5.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2020-2031)
5.3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2020-2031)
6 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Regional Sales and Value Analysis
6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2020-2031)
6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2020-2025
6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2026-2031)
6.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2020-2031)
6.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2020-2025
6.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2026-2031)
6.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
6.6.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
6.7.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
6.8.2 Asia-Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
6.9.2 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2020-2031)
6.10.2 Middle East & Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2024 VS 2031
7 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Country-level Sales and Value Analysis
7.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020-2031)
7.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2020-2025)
7.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2026-2031)
7.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2020-2031)
7.4.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2020-2025)
7.4.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.5.2 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.6.2 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.8.2 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.9.2 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.9.3 France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.11.2 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.12.2 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.13.2 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.16.2 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.16.3 China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.17.2 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.19.2 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.19.3 India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.20.2 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.24.2 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.26.2 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.28.2 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.29.2 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.31.2 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Amgen
8.1.1 Amgen Comapny Information
8.1.2 Amgen Business Overview
8.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.1.5 Amgen Recent Developments
8.2 Mylan
8.2.1 Mylan Comapny Information
8.2.2 Mylan Business Overview
8.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.2.5 Mylan Recent Developments
8.3 Kashiv BioSciences
8.3.1 Kashiv BioSciences Comapny Information
8.3.2 Kashiv BioSciences Business Overview
8.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.3.5 Kashiv BioSciences Recent Developments
8.4 Pfizer
8.4.1 Pfizer Comapny Information
8.4.2 Pfizer Business Overview
8.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.4.5 Pfizer Recent Developments
8.5 Fresenius Kabi
8.5.1 Fresenius Kabi Comapny Information
8.5.2 Fresenius Kabi Business Overview
8.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.5.5 Fresenius Kabi Recent Developments
8.6 Coherus BioSciences
8.6.1 Coherus BioSciences Comapny Information
8.6.2 Coherus BioSciences Business Overview
8.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.6.5 Coherus BioSciences Recent Developments
8.7 Sandoz
8.7.1 Sandoz Comapny Information
8.7.2 Sandoz Business Overview
8.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.7.5 Sandoz Recent Developments
8.8 Italfarmaco SpA
8.8.1 Italfarmaco SpA Comapny Information
8.8.2 Italfarmaco SpA Business Overview
8.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.8.5 Italfarmaco SpA Recent Developments
8.9 Evive Biotech
8.9.1 Evive Biotech Comapny Information
8.9.2 Evive Biotech Business Overview
8.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.9.5 Evive Biotech Recent Developments
8.10 Chugai Pharmaceutical
8.10.1 Chugai Pharmaceutical Comapny Information
8.10.2 Chugai Pharmaceutical Business Overview
8.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.10.5 Chugai Pharmaceutical Recent Developments
8.11 Jiangsu Hengrui Pharmaceuticals
8.11.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
8.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
8.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
8.12 Amoytop Biotech
8.12.1 Amoytop Biotech Comapny Information
8.12.2 Amoytop Biotech Business Overview
8.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.12.5 Amoytop Biotech Recent Developments
8.13 Qilu Pharmaceutical
8.13.1 Qilu Pharmaceutical Comapny Information
8.13.2 Qilu Pharmaceutical Business Overview
8.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.13.5 Qilu Pharmaceutical Recent Developments
8.14 CSPC Baike Biopharma
8.14.1 CSPC Baike Biopharma Comapny Information
8.14.2 CSPC Baike Biopharma Business Overview
8.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.14.5 CSPC Baike Biopharma Recent Developments
8.15 SL Pharm
8.15.1 SL Pharm Comapny Information
8.15.2 SL Pharm Business Overview
8.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.15.5 SL Pharm Recent Developments
8.16 Lunan Pharmaceutical
8.16.1 Lunan Pharmaceutical Comapny Information
8.16.2 Lunan Pharmaceutical Business Overview
8.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2020-2025)
8.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
8.16.5 Lunan Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
9.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Mode & Process
9.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
9.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.